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In 2007, the prevalence of Atopic Dermatitis had increased two to three-fold within the last three decades and affected 15-20% of
young children (Buys, 2007). Current treatment includes the use of both steroid and emollient creams. Current suggestions for the order
of application are contradictory. This study aims to examine the role of the order of application of treatments for Atopic Dermatitis
(AD). Hairless mice (SKH-1) were induced to a mild AD flare-up using 2,4-dinitrochlorobenzene (DNCB) and treated with either 1%
hydrocortisone (Maximum Strength Cortizone 10 cream) alone, 1% hydrocortisone followed by Cetaphil (emollient), or Cetaphil
followed by 1% hydrocortisone. We assessed the efficacy of the treatments by measuring: body weights, area scores, severity scores,
and IgE levels. For all measurements, there were no statistically significant differences observed between the treatment groups or
between the treatment groups and the control untreated group. The findings may be useful in harmonizing human treatment plans in
healthcare.

Introduction
Atopic Dermatitis (AD) presents with several challenging symptoms to
everyday life and to caretakers. Studies have shown the growing
importance of trying to find a treatment regimen that will decrease the
negative effects of AD (Buys, 2007; Eichenfield et. al., 2014; &
Watkins, J. 2015). Without a cure for AD, it is only possible to treat the
symptoms of AD with moisturizers and medicated creams.
Lawton discusses uncertainties that patient and health professionals
have including whether an emollient or topical steroid should be applied
first when treating AD (Lawton, 2014). There is research to support the
underlying assumption that applying an emollient improves treatment
with hydrocortisone compared to hydrocortisone alone (Turpeinen,
1991).
Hydrocortisone is one of the most commonly used topical
corticosteroids. Topical steroids such as hydrocortisone are used in the
treatment of a flare-up or worsening in AD symptoms (Watkins, 2015)
and are usually applied daily (Leung, 1998). AD is a complex disorder,
making hydrocortisone’s mechanism of action difficult to determine
completely. Mehta et. al.’s (1998) proposed mechanism is seen in
Figure 1. Mehta et. al. (1998) proposed that after the DNA binding site
of receptor is exposed, there are two ways that the mechanism will
branch off. This is a result of either the presence or absence of an
inflammatory stimulus. Unfortunately, there are still many unknowns
about the way the inflammation affects the mechanism of protein
alterations, making this one possible proposal for hydrocortisone’s mode
of action. Emollients act on the epidermis, creating an occlusive barrier
and preventing water loss from the skin. Creams are the most common
delivery system for an emollient. Creams are a topical formulation
known for a two-phase treatment (emulsion); two immiscible liquids,
one substance in the other (Lodén, 2003). Cetaphil, according to Hon,
Leung, and Barankin (2013) is a barrier cream that contains dimethicone,
a water-repellent substance, that helps to protect the skin from irritants
and repeated hydration.
Eichenfield et.al. (2014) defined a guideline that acute areas of AD
are recommended to have once-daily application until the affected area
has significantly improved or is less thick. Buys (2007) looked at
clinical trials and showed that topical corticosteroids (hydrocortisone in
the experiment) are effective when used up to four weeks based on
previous research (Lebwohl, 1999; Maloney et. al., 2002; Sears, Bailer,
& Yeadon, 1997). These clinical trials also show that in many cases
symptoms may be controlled within a shorter treatment time (Buys,
2007; Lebwohl, 1999; Maloney et. al., 2002; Sears, Bailer, & Yeadon,
1997).
In the present study, we evaluated the hypothesis that the order of
application of 1% hydrocortisone cream and Cetaphil (emollient) is
significant to the treatment of AD in a two-week treatment period. The
effects of the orders were assessed using hairless mouse model of 2,4dinitrochlorobenzene (DNCB) – induced AD.

Figure 1. Proposed mechanism of glucocorticoid (hydrocortisone)
action (Mehta et. al., 2016).

Methods
Animals. Three-week-old male SKH-1 Elite mice were purchased from
Charles River and all the procedures were performed in accordance with
the Guide for the Care and Use of Laboratory Animals: Eighth Edition
(National Research Council Committee for the Update of the Guide for
the Care and Use of Laboratory, 2011). Before the experiment started,
the animals were acclimated for nine days. The animals were housed in
a temperature and humidity controlled (22°C) room with a 12-hour light
and dark cycle. The mice were also allowed free access to food and
water throughout the experiment.
Grouping. Mice were randomly divided into four groups: control
without treatment, hydrocortisone-treated group only, hydrocortisone
applied first and after 30 minutes Cetaphil was applied, and emollient
applied first and after 30 minutes hydrocortisone was applied. When the
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mice were obtained, they were immediately weighed, ear punched (for Results
identification), and were randomly selected for each cage (four mice in
each cage, with one cage of five). At the end of acclimation, the cage Statistical Analysis. GraphPad software (Prism, San Diego, CA, USA)
numbers were placed into a container and drawn at random to assign the was used to plot graphs. One-way and two-way analysis of variance
treatment/no treatment that each of the cages would receive.
(ANOVA) with Bonferroni’s post-tests were used to perform the
Induction of AD. Induction of AD was performed using DNCB, as statistical analyses of the data.
previously described (Kim et al., 2014), with minor modification.
DNCB was mixed in a solution of 1:4 acetone and olive oil, respectively, Body Weight. As seen in Figure 3, there is a steady increase in weight
to make a 1% solution. The solution was then placed on an adhesive during the acclimation period (the first 3 data points) this indicates the
gauze (clear spot Band-Aid). The Band-Aids were placed on the lower mice were growing, as to be expected with young mice (3 weeks old).
back of the mice for 24-hour periods on days 10, 12, 17, and 19 of the There was a slower increase during the sensitization period until the
second week’s sensitizing that showed variation in the body weights at
study (Figure 2).
the end of the study. The body weights for the treatment phase climaxed
Treatment. Once the AD was induced, treatment began on day 20 on day 25 for the three treatment groups (the control dropped slightly)
(Figure 2). Hydrocortisone cream (Maximum Strength Cortizone 10 and continued to drop, while the control increased and leveled out for
cream) 0.9 grams was measured out using a scupula and scale. the last week of the experiment. There was no significant difference in
Hydrocortisone was applied to the back of the mice where the AD-like the weights of the mice from each group at any point during the
lesions were located. Once applied the scupula was measured again to experiment indicating that there is no correlation with the significance of
try to reduce the amount of loss of cream and maintain an average of 0.9 the order.
grams of cream per mouse.
Combined treatments used both Area Scores. The control, hydrocortisone only, and the Cetaphil and
hydrocortisone and Cetaphil (emollient used, 0.9g of the cream was hydrocortisone group all showed a decrease in AD-like lesion area size
measured and applied) on the backs of mice. The procedure for applying throughout the study (Figure 4), whereas hydrocortisone and Cetaphil
the creams to the backs were the same in all the treatments. The showed a decrease between the first two collection days and the last day
combined treatments had a 30-minute wait time in between the showed a slight increase in the area score. However, there were no
application of the first and the second cream.
statistically significant difference between the treatment groups in lesion
Body Weight. Body weights for each of the mice were observed at every area size throughout the experiment.
bedding change, twice weekly. Body weights were collected to observe
the health of the mice and to see if there was any noticeable correlation Severity Scores. Figure 5 shows the mean severity scores increased in
all groups during the sensitization phase and continued to rise at the start
when sensitized and treated.
of the treatment period. Each group then had severity scores return to
Area Scores. The area scores were measured on the blood collection near zero by the end of the study. There was no significant difference
days (once a week following sensitization period). While the mice were between the treatment groups.
anesthetized, AD-like lesion size was measured. Measurements were
IgE ELISA. As shown in Figure 6, IgE was significantly higher than
taken of the longest and widest dimensions of AD-like lesions.
control in the hydrocortisone only group on day 20 (p<0.01). When
Severity scores. Using a modified form of the EASI score as previously comparing between days in the treatment groups, neither the
described by Hanifin (2001), the lesions of each mouse was scored on a hydrocortisone followed by the Cetaphil or the Cetaphil followed by the
scale of 0-3 for each of the following criteria: redness, scaling, and hydrocortisone showed a significant reduction in IgE during the
thickness. After the sensitization, the mice were scored by two members treatment period. The control group showed a significant increase in IgE
of the research team every day for the span of the experiment. The mean between day 20 and 27 (p<0.05) and a significant reduction between day
scores were taken from each day’s scores and the standard deviations 27 and day 35 (p<0.01). The hydrocortisone only group showed no
were calculated.
significant difference between day 20 and 27 but there was a significant
Blood Collection.
Blood collection began immediately after decrease between day 27 and day 35 (p<0.05). This is likely due to such
sensitization on day 20 with a week between each collection (Figure 2). a high start value for the IgE levels for the hydrocortisone only group
On blood collection days, the mice were not treated. Mice from each compared to the other groups. Looking at Figure 6 there appears to be
group were anesthetized and blood was collected via tail venipuncture. no significance in the order of application.
As blood pooled on the surface, it was collected in Capillary Blood
Collection Tubes. The serum was collected and then frozen at 4°C until
further testing.
ELISA. An IgE ELISA was performed using the serum collected. The
ELISA test was conducted according to the ELISA kit instructions (BD
Biosciences OptEIA Set Mouse IgE kit).

Figure 2.
Timeline of the acclimation, sensitization, and
treatment. Mice acclimated days 1-9 and were given free access to
food and water. The mice were sensitized on days 10, 12, 17, &
19 using 1% DNCB in a vehicle of 1:4 acetone and olive oil
respectively, on Band-Aids. Treatment began on day 20 and
continued throughout the experiment followed by sacrifice on the
35th day.

Figure 3. Representation of the mean weights of the mice in each of
the treatment groups. The brackets represent the standard deviation
per treatment group.
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Figure 6. Above illustrates the IgE levels in the serum collected on
days 20, 27, and 35. On day 11 (start of the treatment phase) there
was a significant difference between hydrocortisone only and
control (p<0.01). When comparing between days in the treatment
groups, neither the hydrocortisone followed by the Cetaphil or the
Cetaphil followed by the hydrocortisone showed a significant
reduction in IgE during the treatment period. The control group
showed a significant increase in IgE between day 20 and 27
(p<0.05) and a significant reduction between day 27 and day 35
(p<0.01). The hydrocortisone only group showed no significant
difference between day 20 and 27 but there was a significant
decrease between day 27 and day 35 (p<0.05). Looking at the
comparison graph there appears to be no significance in the order
of application. *p<0.05, **p<0.01.

Figure 4. Mean Lesion Area - of the longest and widest AD-like
lesions. The area scores decrease during the study. The control is
not significantly different from the treatment regimens at any
point throughout the experiment.

patient that the order of the application is not significant to the treatment
efficacy; as much as different articles recommending that there is at least
a 30-minute absorption wait time in between the two applications
(Lawton, 2014). From our data, the hydrocortisone and emollient
compared to hydrocortisone shows that there is not a significant
difference in the treatment regimens.
Limitations of the experiment were ways to measure area scores, blood
collection, and limited sample size. The area scores were difficult to
measure because some of the mice had large scabs that made it difficult
to measure the area affected. The mice were small and only 100 μL of
blood could safely be collected from the mice every seven days. The
experiment groups only had four mice, which produces a fairly small
statistical power.

Figure 5. Mean severity scores for the treatment groups start on
the 10th day throughout the study. The severity scores are a
mean sum of three factors: redness, thickness, and scaling/
dryness. There is a climax of severity scores of the treatment
groups at the start of the treatment phase of the experiment. The
severity scores continue to decrease until the end of the study.

Further investigation is necessary to add to the statistical power of the
current study. Based on conclusions found in this experiment, future
studies are needed to determine the optimum time in between the
application. Also, repeat the current study with the appropriate time
between applications in the combined treatment groups.

Discussion
There seems to be no significance to the order of application of
hydrocortisone and Cetaphil when comparing weight, area, severity
scores, and IgE production. The hydrocortisone-Cetaphil combination
treatment may be preventing an increase in IgE (that is seen in the
control group on day 27), but there was no significant decrease in IgE in
these treatment groups. These results do not support the alternative
hypothesis that the order of application is significant to the treatment of
Atopic Dermatitis. Clinically speaking this is not far from what some
doctors already thought. Smoker & Voegeli (2014) conducted a critical
review looking at 27 recommendations for the order of application and
the time intervals and found that there were two main treatment
recommendations: topical steroid should be applied first, then wait 30
minutes and apply the emollient or apply emollient first then wait 30
minutes and apply the topical steroid. Our data concurs that the order of
the application is not significant. Physicians should be able to tell the

Acknowledgements
Tequestia Felton, Research Assistant; Dr. Steven Hayduk, Honor’s
Committee; Prof. Staci Johnson, Honor’s Committee; Dr. Steven
Hayduk, Honor’s Committee; Southern Wesleyan University Honor’s
Oversight Committee; South Carolina Independent Colleges and
Universities for funding; and Clemson’s Godley Snell Research Center

Notes and References
*Corresponding author email: ashlee.tietje@indwes.edu
Brown, S., & Reynolds, N. J. (2006). Atopic and non-atopic eczema. British
Medical Journal (Clinical Research Ed.), 332(7541), 584-588.

Journal of the South Carolina Academy of Science, [2018], 16 (1) | 27

Undergraduate Research Article
Brown, S. J. (2016). Atopic eczema. Clinical Medicine, 16(1), 66-69.
Buys, L. M. (2007). Treatment options for atopic dermatitis. American Family
Physician, 75(4), 523-528.
National research council committee for the update of the guide for the care and
use of laboratory (2011). Guide for the Care and Use of Laboratory Animals
(8th ed.). Washington: National Academies Press.
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S.,
Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper,
K. D., Cordoro, K. M., Davis, D. M., Feldman S. R., Hanifin, J. M.,
Margolis, D. J., Silverman, R. A., Simpson, E. L. Williams, H. C., Elmets, C.
A., Block, J., Harrod, C. G., Begolka, W. S., & Sidbury, R. (2014).
Guidelines of care for the management of atopic dermatitis: Section 2.
Management and treatment of atopic dermatitis with topical therapies.
Journal of the American Academy of Dermatology, 71(1), 116-132.
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M. &
Evaluator Group, T. E. (2001). The eczema area and severity index (EASI):
Assessment of reliability in atopic dermatitis. Experimental Dermatology, 10
(1), 11–18.
Hon, K., Leung, A., & Barankin, B. (2013). Barrier repair therapy in atopic
dermatitis: An overview. American Journal Of Clinical Dermatology, 14(5),
389-399.
Kubo, A., Nagao, K., & Amagai, M. (2012). Epidermal barrier dysfunction and
cutaneous sensitization in atopic diseases. The Journal Of Clinical
Investigation, 122(2), 440-447.
Lawton, S. (2014). Atopic eczema: The current state of clinical research. British
Journal of Nursing, 23(20), 1061-1066.
Lebwohl M. (1999). A comparison of once-daily application of mometasone
furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2%
cream in pediatric atopic dermatitis patients who failed to respond to
hydrocortisone: Mometasone furoate study group. International Journal of
Dermatology, 38(8), 604-606.
Lee, K. S., Jeong, E. S., Seo, J. H., Jeong, D. G., & Choi, Y. K. (2010). A novel
model for human atopic dermatitis: Application of repeated DNCB patch in
BALB/c mice, in comparison with NC/Nga mice. Laboratory Animal
Research, 26(1), 95-102.
Leung D.Y. (1999). Pathogenesis of atopic dermatitis. The Journal of Allergy and
Clinical Immunology, 104(3), S99-S108.
Lodén, M. (2003). Role of topical emollients and moisturizers in the treatment of
dry skin barrier disorders. American Journal of Clinical Dermatology, 4(11),
771-788.
Maloney J. M., Morman M. R., Stewart D. M., Tharp M. D., Brown J. J.,
Rajagopalan R. (2002). Clobetasol propionate emollient 0.05% in the
treatment of atopic dermatitis. International Journal of Dermatology, 37(2),
142-4.
Mehta, A. B., Nadkarni, N. J., Patil, S. P., Godse, K. V., Gautam, M., & Agarwal,
S. (2016). Topical corticosteroids in dermatology. Indian Journal of
Dermatology, Venereology & Leprology, 82(4), 371-378.
Peacock, S. (2016). Use of emollients in the management of atopic eczema.
British Journal Of Community Nursing, 21(2), 76-80.
Sears H. W., Bailer J. W., Yeadon A. (1997). Efficacy and safety of
hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis.
Clinical Therapy, 19(4),710-9.
SKH1-Elite Mouse (n.d.). Retrieved from: https://www.criver.com/productsservices/find-model/skh1-elite-mouse?region=3611.
Turpeinen, M. (1991). Absorption of hydrocortisone from the skin reservoir in
atopic dermatitis. The British Journal of Dermatology, 124(4), 358-360.
Watkins, J. (2015). Managing atopic eczema in adults. Practice Nursing, 26(2),
62-67.
Williams, H. (2005). Atopic dermatitis. The New England Journal of Medicine,
352(22), 2314-2324.
Zesch, A., & Schaefer, H. (1975). [Penetration of radioactive hydrocortisone in
human skin from various ointment bases. II. In vivo-experiments (author's
transl)]. Archiv Für Dermatologische Forschung, 252(4), 245-256.

Journal of the South Carolina Academy of Science, [2018], 16 (1) | 28

